On Friday, Cytokinetics Inc (NASDAQ: CYTK) opened lower -4.27% from the last session, before settling in for the closing price of $38.89. Price fluctuations for CYTK have ranged from $29.31 to $61.38 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -20.02% annually for the last half of the decade. Company’s average yearly earnings per share was noted -8.95% at the time writing. With a float of $116.79 million, this company’s outstanding shares have now reached $119.22 million.
In an organization with 498 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -1359.51%, operating margin of -2943.3%, and the pretax margin is -3201.47%.
Cytokinetics Inc (CYTK) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cytokinetics Inc is 2.21%, while institutional ownership is 116.10%. The most recent insider transaction that took place on Jul 14 ’25, was worth 190,750. In this transaction President & CEO of this company sold 5,000 shares at a rate of $38.15, taking the stock ownership to the 393,108 shares. Before that another transaction happened on Jul 08 ’25, when Company’s Officer proposed sale 14,000 for $33.36, making the entire transaction worth $467,040.
Cytokinetics Inc (CYTK) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -8.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.60% during the next five years compared to -20.02% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Check out the current performance indicators for Cytokinetics Inc (CYTK). In the past quarter, the stock posted a quick ratio of 5.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 231.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.31, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -5.06 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Let’s dig in a bit further. During the last 5-days, its volume was 1.58 million. That was inferior than the volume of 1.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.96%.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 40.91%, which indicates a significant decrease from 67.11% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.42 in the past 14 days, which was lower than the 1.90 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.21, while its 200-day Moving Average is $43.81. However, in the short run, Cytokinetics Inc’s stock first resistance to watch stands at $38.83. Second resistance stands at $40.43. The third major resistance level sits at $41.39. If the price goes on to break the first support level at $36.27, it is likely to go to the next support level at $35.31. The third support level lies at $33.71 if the price breaches the second support level.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
There are currently 119,427K shares outstanding in the company with a market cap of 4.45 billion. Presently, the company’s annual sales total 18,470 K according to its annual income of -589,530 K. Last quarter, the company’s sales amounted to 1,580 K and its income totaled -161,380 K.
